<DOC>
	<DOCNO>NCT00857870</DOCNO>
	<brief_summary>Comparison efficacy safety glargine insulin metformin first line drug patient insufficiently treat lifestyle intervention . So far treatment also algorithm lifestyle metformin evaluate patient type 2 diabetes HbA1C great equal 7 % low 8.1 % .Besides HbA1C postprandial glucose excursion glycemic variability determinant oxidative stress measure continuous glucose measurement ( CGM ) . Further CGM reveal risk hypoglycemia night . As secondary objective effect endothelial function , renal function biomarkers low great inflammation evaluate . So far scarce information face face comparison ealy diabetes exists .</brief_summary>
	<brief_title>Insulin Glargine First Line v Metformin Type 2 Diabetic Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>early type 2 diabetes ( low 5 year know ) male female ( 35 75 year ) HbA1c 7 8 % , drug naive &lt; = 8.5 previous OAD intake Informed consent treatment one OAD time treatment one OAD &lt; 6 week time insulin treatment acute coronary syndrome &lt; 6 month severe liver disease alcohol abuse drug addiction severe kidney disease acute critical illness renal impairment i.v . application iodine ketoacidosis acute chronic illness witch may lead hypoxia cardial failure allergy one drug deficit compliance cooperation pregnancy breast feed woman fertile age without accepted contraceptive</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>